AOD-9604 compounding pharmacy vs research supplier: what's real

Last updated 2026-07-25

Does AOD-9604 actually work for fat loss in humans?

Here's the part nobody selling this peptide wants to lead with: the human obesity trial data on AOD-9604 did not produce a clean win over placebo. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile describes it as a modified fragment of human growth hormone (hGH 176-191) designed to isolate the fat-metabolizing region of the GH molecule while dropping the growth-promoting and diabetogenic effects ^[1]. That's the whole rationale for the drug: take the piece of GH that seems to drive lipolysis, leave out the piece that grows bone and raises blood sugar. The idea was reasonable enough that Australian biotech Metabolic Pharmaceuticals ran it through Phase II human obesity trials in the mid-2000s. A 2006 survey of obesity drugs in clinical development covers AOD-9604 among the pipeline candidates of that era ^[2]. What came out the other side was underwhelming: reported weight-loss effects in the human trials were small and did not separate convincingly from placebo across the trial program. That's not a matter of opinion, it's why the drug never advanced to an approved obesity medication and never appears in the FDA's approved drug database [see Drugs@FDA, cited below]. If you're weighing AOD-9604 against something with a real efficacy signal, read aod 9604 peptide for the full trial history, or compare it directly against aod 9604 vs tesamorelin, which has FDA approval for a different indication (HIV-associated lipodystrophy) and a much deeper efficacy record. So the honest starting point for this whole comparison is: neither a compounding pharmacy nor a research supplier is selling you a proven fat-loss drug. They're selling you the same molecule with a proven weak trial record. The difference between the two channels is what happens around the molecule, not what the molecule does once it's in you.

What is a compounding pharmacy route, exactly?

A compounding pharmacy route means a state-licensed pharmacy prepares the peptide for a specific patient under a prescriber's order, using standards set by federal and state pharmacy law rather than selling a generic research vial to anyone with a credit card. Under federal law, pharmacy compounding is governed by 21 U.S.C. 353a, which lays out the conditions under which a licensed pharmacist can compound a drug for an identified patient based on a valid prescription, using ingredients that meet applicable United States Pharmacopeia or National Formulary standards, or, where the ingredient isn't in an approved drug and has no such monograph, ingredients that are components of FDA-approved drugs or appear on FDA's 503A bulk drug substances list ^{[3] [4]}. That 503A list matters a lot here, and this is the detail most sourcing pages skip. The FDA maintains a running Bulks List under 21 CFR 216.23 for substances that may be used in 503A pharmacy compounding ^[5], and a separate 503B list under 21 CFR 216.24 for outsourcing facilities that compound in larger batches without individual prescriptions ^[6]. FDA's own bulk drug substances page for 503A explains the nomination and evaluation process pharmacies and sponsors go through to get a substance added ^[4], and FDA publishes the current roster of substances nominated for that list ^[7]. Whether AOD-9604 sits on either list, and under what conditions, is exactly the kind of detail a legitimate compounding pharmacy will have already checked before it fills your script, because working outside that framework is a regulatory problem for the pharmacy, more than for you. The practical upshot: a compounding pharmacy route usually means a prescriber reviews your health history, a pharmacist checks the order against sourcing rules, and the vial ships from a facility that answers to a state board of pharmacy. That's a fundamentally different liability and quality chain than a research chemical seller.

What is a research supplier route, and what are you actually getting?

A research supplier route means you're buying a vial labeled 'for laboratory use only' or 'not for human consumption' from a company that sells peptides as research chemicals, with no prescriber, no pharmacist, and no clinical oversight anywhere in the chain. That label isn't decoration. Under 21 CFR 201.128, FDA's rule on the meaning of intended use looks at the actual circumstances of sale and marketing, more than the words on the label, to determine whether a product is being offered as a drug ^[8]. A supplier can print 'research use only' on the vial while marketing dosing schedules, injection guides, and fat-loss testimonials on the same website, and that gap between label and marketing is precisely the kind of thing that draws regulatory attention. For the buyer, though, the immediate problem is simpler: there's no pharmacist checking purity, no prescriber checking your medical history, and no chain of custody proving the vial contains what the label says at the concentration it says. Research suppliers also operate completely outside the 503A/503B bulk substance framework ^{[5] [6] [4]}. That's not a technicality. It means nobody with pharmaceutical training has verified the raw material sourcing, and there's no equivalent of a pharmacy's compounding standards governing how the vial was made, stored, or shipped.

Compounding pharmacy vs research supplier: side-by-side

The table makes the real point obvious: sourcing quality and clinical evidence are two separate questions. A compounding pharmacy can hand you a well-made, properly reviewed vial of a peptide whose obesity trial data still didn't beat placebo convincingly. Better sourcing doesn't manufacture efficacy that isn't there.

Why does the trial record matter more than where you buy it?

Because no purchase channel can retroactively fix a weak Phase II result. This is the single most important thing to understand before comparing vendors. The 2004 metabolic profile review of AOD-9604 ^[1] and the 2006 obesity drug pipeline survey ^[2] together tell the actual story: a hGH fragment engineered to isolate the lipolytic region of growth hormone, tested in human obesity trials, that did not produce weight loss clearly separating from placebo. That's a scientific outcome, and it's the same outcome whether you buy the peptide from a five-star-reviewed compounding pharmacy or a bargain research supplier. A newer 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics discusses AOD-9604 and similar peptides in the broader context of applications, challenges, and future directions for peptide therapeutics, without establishing a new efficacy claim for fat loss ^[9]. Similarly, a 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance places AOD-9604 among the unapproved peptides circulating in that space, again in a safety-and-context frame rather than a proof-of-efficacy frame ^[10]. Neither of these more recent papers overturns the earlier trial finding. If anything, the fact that AOD-9604 keeps showing up in review articles about peptides generally, rather than in new dedicated obesity trials, tells you where the research investment actually went after the mid-2000s: away from fat loss. For context on where this fragment came from and how the dosing logic is supposed to work, see aod 9604 peptide and when to take aod 9604 peptide.

Does AOD-9604 show up on doping tests, and does that affect sourcing?

AOD-9604 does not trigger the World Anti-Doping Agency's hGH isoform immunoassay, according to a 2013 study in Drug Testing and Analysis that tested the fragment specifically against that assay and found no interference ^[11]. That's a narrow, specific finding: it means this one detection method doesn't flag AOD-9604 as hGH, not that the peptide is undetectable by every method or that it's cleared for competitive sport. Other analytical work has focused on catching small peptides like AOD-9604 through different routes. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting emerging therapeutics and non-approved drugs in doping controls covers analytical approaches built to catch exactly this category of compound ^[12]. A 2014 Expert Review of Proteomics paper on detecting peptidic drugs and analogs in sports doping lays out the broader detection landscape for small peptide drugs and drug candidates ^[13]. And a 2016 paper in the Journal of Separation Science describes a method for screening peptides under 2 kDa (AOD-9604 is a fragment in that low molecular weight range) directly from urine using liquid chromatography and ion mobility mass spectrometry ^[14], which suggests detection science for this size of peptide has kept moving even where the isoform immunoassay doesn't catch it. Why mention this in a sourcing article? Because if you're an athlete under any testing authority, the sourcing question isn't just 'is this pharmacy licensed,' it's 'am I risking a sanction regardless of where I bought it.' Neither a compounding pharmacy nor a research supplier changes what testing labs are capable of finding.

What does 'clinical trials gateway' actually mean for AOD-9604's evidence base?

A trio of papers titled 'Gateways to clinical trials,' published in Methods and Findings in Experimental and Clinical Pharmacology in 2003 and 2005, track AOD-9604 among a roundup of compounds moving through various stages of clinical development during that period ^{[15] [16] [17]}. These aren't dedicated AOD-9604 efficacy studies; they're periodic industry-tracking roundups that mention where various drug candidates sit in the pipeline. That distinction matters for anyone reading citation lists on seller websites. A compound showing up in a 'gateways to clinical trials' roundup means it was in development and being tracked, not that it passed a trial. AOD-9604's actual efficacy data comes from the obesity trial results referenced in the 2004 and 2006 reviews ^{[1] [2]}, and those are the results that didn't separate from placebo convincingly. If a supplier's site cites 'multiple clinical trials' for AOD-9604 without naming the specific outcome of those trials, that's a marketing tell, not evidence.

How do I check if a compounding pharmacy is legitimate?

Ask three things before you order: is the pharmacy licensed in your state, does it require a prescription from a licensed prescriber, and can it explain (not dodge) whether the substance it's compounding is on FDA's 503A bulk drug substances list. A pharmacy that skips the prescriber step, that ships without any medical intake, or that can't answer a direct question about bulk substance sourcing under 21 CFR 216.23 ^[5] is behaving like a research supplier wearing a pharmacy's name. Legitimate compounding under 21 U.S.C. 353a requires an identified, individual patient and a valid prescription ^[3]. There's no legal path around that for a 503A pharmacy. This is also where a provider-reviewed sourcing model earns its keep. AOD-9604 Co's role in this landscape is to route interested readers toward a provider-reviewed path (a licensed prescriber and a named, accountable compounding pharmacy partner) instead of an anonymous vial seller, precisely because the sourcing chain is the one variable a buyer can actually control here. The efficacy question stays the same either way; the chain-of-custody question does not.

What should I actually do if I'm considering AOD-9604?

Read the trial record first, then decide if the sourcing question even matters to you. If a modest, unproven fragment isn't worth pursuing once you know the Phase II obesity data didn't separate from placebo ^{[1] [2]}, no vendor comparison changes that math. If you've read the evidence and still want to move forward, don't buy from an anonymous research supplier with no prescriber and no pharmacist in the loop. Go through a route where a licensed prescriber reviews your history and a named compounding pharmacy fills the order under the 503A framework ^{[3] [5]}. Check best place to buy aod 9604 and aod 9604 peptide for sale for more on vetting specific sourcing options, and how to reconstitute AOD-9604 if you're already holding a vial and need the mixing basics right. And if your actual goal is fat loss with real trial support behind it, spend some time on aod 9604 vs tesamorelin before you commit budget to AOD-9604 specifically. Tesamorelin has FDA approval for a defined indication and a materially deeper clinical record; that's not a small difference.

Frequently asked questions

Is AOD-9604 FDA-approved for weight loss?

No. AOD-9604 does not appear in FDA's Drugs@FDA database of approved drug products. Its human obesity trials, summarized in a 2004 metabolic profile review and a 2006 obesity drug pipeline survey, did not show weight loss clearly separating from placebo, which is a central reason it never reached approval.

Can a compounding pharmacy legally make AOD-9604?

Legitimate 503A compounding requires an individual prescription under 21 U.S.C. 353a and sourcing that fits FDA's bulk drug substances framework under 21 CFR 216.23. Whether AOD-9604 qualifies depends on its current status on that list; a legitimate pharmacy should be able to explain that status directly rather than avoiding the question.

What's the difference between 503A and 503B compounding?

503A covers pharmacies compounding for an identified patient under a valid prescription, governed by 21 CFR 216.23. 503B covers outsourcing facilities that compound larger batches without individual prescriptions, governed by 21 CFR 216.24. Both rely on FDA bulk drug substance lists to determine which ingredients are permitted.

Is buying AOD-9604 from a research supplier illegal?

It exists in a gray zone. Products labeled 'research use only' can still trigger FDA's intended-use scrutiny under 21 CFR 201.128 if marketing and sale circumstances suggest human consumption. There's no prescriber or pharmacist oversight in this channel, which is a separate problem from the label's legal status.

Does AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not trigger WADA's hGH isoform immunoassay specifically. That doesn't mean it's undetectable by all methods; separate analytical work has developed other approaches for catching small peptides like AOD-9604 in urine screening.

Why didn't AOD-9604 get FDA approval if the fragment rationale made sense?

The rationale, isolating the fat-metabolizing region of growth hormone while dropping the growth and blood-sugar effects, was scientifically plausible. But Phase II human obesity trials, summarized in reviews from 2004 and 2006, showed weight-loss effects too small to separate convincingly from placebo, which stalled its path forward.

Is a compounding pharmacy vial of AOD-9604 more effective than a research supplier vial?

No. Sourcing quality affects purity, accuracy of concentration, and safety oversight, not the underlying efficacy of the molecule. The same weak Phase II trial data applies regardless of which vendor type you buy from.

What questions should I ask before buying from any AOD-9604 seller?

Ask whether a prescriber reviews your history, whether the compounding pharmacy is licensed in your state, whether the source substance fits FDA's 503A bulk drug list framework, and whether the seller can name a real study for any efficacy claim rather than a vague 'clinical trials' reference.

How is AOD-9604 different from tesamorelin?

Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has a substantially deeper clinical trial record. AOD-9604 is an unapproved hGH fragment whose obesity trials did not separate from placebo convincingly. See the direct comparison for dosing and evidence differences.

Are 'gateways to clinical trials' papers proof that AOD-9604 works?

No. Those 2003 and 2005 papers in Methods and Findings in Experimental and Clinical Pharmacology are periodic pipeline-tracking roundups noting which compounds were in development, not dedicated efficacy studies. AOD-9604's actual trial outcome is reported separately, and it was weak.

What does 'research use only' actually mean on a peptide vial?

It's a label suggesting the product isn't meant for human use, but FDA's intended-use rule under 21 CFR 201.128 looks at the real marketing and sale circumstances. A label alone doesn't establish legal status if the surrounding marketing points toward human consumption.

Should athletes worry about AOD-9604 in doping tests regardless of sourcing?

Yes. Detection capability depends on the testing method used, not on where you bought the peptide. A 2013 study found AOD-9604 doesn't affect the WADA hGH isoform immunoassay, but other analytical methods developed since 2014 target small peptides specifically.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604 is a hGH 176-191 fragment designed to isolate fat-metabolizing effects; human obesity trial weight-loss results did not separate convincingly from placebo
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 appears among obesity drugs in clinical development as of 2006, contextualizing its trial-stage status
3. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Federal statute governing pharmacy compounding requirements including valid prescription and identified patient
4. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains FDA's process for evaluating and nominating bulk drug substances for 503A compounding use
5. eCFR, 21 CFR 216.23 (503A Bulks List): Federal regulation establishing the list of bulk drug substances permitted for 503A pharmacy compounding
6. eCFR, 21 CFR 216.24 (503B Bulks List): Federal regulation establishing the list of bulk drug substances permitted for 503B outsourcing facility compounding
7. FDA, Bulk Drug Substances Nominated for Use in Compounding: Current FDA list of substances nominated for 503A bulk drug substance evaluation
8. eCFR, 21 CFR 201.128: Federal rule defining intended use based on actual marketing and sale circumstances, more than product labeling
9. PubMed, JAAOS Global Research & Reviews (2026): 2026 review discusses AOD-9604 among therapeutic peptides in orthopaedics, covering applications, challenges and future directions
10. PubMed, Sports Medicine (2026): 2026 review places AOD-9604 among unapproved peptide therapies used for musculoskeletal injuries and athletic performance
11. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay, per direct testing study
12. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Describes analytical approaches for detecting emerging therapeutics and non-approved drugs, including small peptides, in doping controls
13. PubMed, Expert Review of Proteomics (2014): Reviews current status and future directions for detecting peptidic drugs and analogs in sports doping
14. PubMed, Journal of Separation Science (2016): Describes a direct urine injection LC-ion mobility mass spectrometry method for screening peptides under 2 kDa
15. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateways to clinical trials roundup tracking compounds including AOD-9604 in development as of 2003
16. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Second 2003 gateways to clinical trials roundup tracking compounds in the drug development pipeline
17. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 gateways to clinical trials roundup tracking compounds including AOD-9604 in later-stage pipeline tracking